Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

601. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia

Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia Tunis S L, Johnstone B M, Gibson P J, Loosbrock D L, Dulisse B K Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Olanzapine in the treatment of schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-consequences analysis. Study population The study evaluated patients

1999 NHS Economic Evaluation Database.

602. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial Hamilton S H, Revicki D A, Edgell E T, Genduso L A, Tollefson G Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Olanzapine compared with haloperidol for treatment of schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population US-residing patients with schizophrenia who were at least 18 years

1999 NHS Economic Evaluation Database.

603. Clozapine for refractory schizophrenia: the Illinois experience

Clozapine for refractory schizophrenia: the Illinois experience Clozapine for refractory schizophrenia: the Illinois experience Clozapine for refractory schizophrenia: the Illinois experience Buckman R W, Malan R D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Clozapine for refractory schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study consisted of hospitalised treatment-resistant schizophrenia patients. Setting Hospital and community. The economic study was carried out in the USA. Dates to which data relate Data about the effectiveness of clozapine for refractory schizophrenia were collected between 1990 and 1995. Cost data were obtained from estimates

1999 NHS Economic Evaluation Database.

604. Evidence-based nursing - treatment of people with schizophrenia

Evidence-based nursing - treatment of people with schizophrenia Evidence-based nursing - treatment of people with schizophrenia Evidence-based nursing - treatment of people with schizophrenia Hellzn O, Johanson A, Pejlert A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hellzn O, Johanson A, Pejlert A. Evidence-based nursing - treatment (...) of people with schizophrenia. Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 1999: 71 Authors' objectives This review summarises the available evidence on the nursing care of people with schizophrenia. Authors' conclusions In Western countries, the emphasis in psychiatric care has shifted from inpatient care to outpatient services. This change means that people with schizophrenia must have access to a functioning family and support network. The scientific evidence presented

1999 Health Technology Assessment (HTA) Database.

605. Drug treatments for schizophrenia

Drug treatments for schizophrenia Drug treatments for schizophrenia Drug treatments for schizophrenia NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Drug treatments for schizophrenia. University of York. Effective Health Care 5(6). 1999 Authors' objectives (...) This report summarises the research evidence on drug treatments for schizophrenia. Authors' conclusions Schizophrenia is one of the most common of the severe mental illnesses. Drug treatment with antipsychotics forms the mainstay of effective management, but should be used alongside a range of psychosocial interventions. The newer 'atypical' antipsychotics may be a further refinement, but not a revolution, in the care of those with schizophrenia. They may cause less adverse effects and be more acceptable

1999 Health Technology Assessment (HTA) Database.

606. Exercise as an adjunct treatment for schizophrenia: a review of the literature

Exercise as an adjunct treatment for schizophrenia: a review of the literature Exercise as an adjunct treatment for schizophrenia: a review of the literature Exercise as an adjunct treatment for schizophrenia: a review of the literature Faulkner G, Biddle S Authors' objectives To examine the literature investigating the use of exercise as a therapeutic adjunct treatment for schizophrenia. Searching The Social Sciences Citation Index and EMBASE via BIDS, PsycLIT, MEDLINE and SPORTDiscus were (...) . Participants included in the review Adults with schizophrenia. All patients had diagnoses of chronic schizophrenia and included male and female out-patients, in-patients, and sheltered accommodation patients. Outcomes assessed in the review The authors did not specify any inclusion or exclusion criteria relating to outcomes. Standard psychological instruments used included the Beck Depression Inventory (BDI), the Mental Health Inventory (MHI), Brief Psychotic Rating Scale (BPRS), the Nurses' Observation

1999 DARE.

607. Treatment of schizoaffective disorder and schizophrenia with mood symptoms

Treatment of schizoaffective disorder and schizophrenia with mood symptoms Treatment of schizoaffective disorder and schizophrenia with mood symptoms Treatment of schizoaffective disorder and schizophrenia with mood symptoms Levinson D F, Umapathy C, Musthaq M Authors' objectives To review the literature on treatment of two overlapping groups of patients: those with schizoaffective disorder and those with schizophrenia and concurrent mood symptoms. Searching MEDLINE (1976 onwards) was searched (...) for schizophrenia and schizoaffective disorders (no further restrictions were described a priori). Interventions reported in the review included: antidepressants (amitriptyline, nortriptyline, imipramine, viloxazine, maprotiline, trazodone, bupropion), atypical antipsychotics (clozapine, risperidone, olanzapine), anticonvulsants (sodium valporate, carbamazepine), neuroleptics (chlorpromazine, haloperidol, thioridazine, fluphenazine decanoate, flupenthixol decanoate, molindone, perphenazine, thiothixene

1999 DARE.

608. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis Keefe R S, Silva S G, Perkins D O, Lieberman J A Authors' objectives To critically review studies of the impact of atypical antipsychotics (...) on cognitive deficits in patients with schizophrenia. Searching MEDLINE and Psychological Abstracts were searched, and relevant articles published between 1990 and April 1998 were then reviewed. Data from a paper in press, which described additional measures in an already published study, were also included. Study selection Study designs of evaluations included in the review The authors do not specifically state the study design inclusion and exclusion criteria used to select studies for inclusion

1999 DARE.

609. Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. (PubMed)

Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. To investigate whether intensive cognitive behaviour therapy results in significant improvement in positive psychotic symptoms in patients with chronic schizophrenia.Patients with chronic schizophrenia were randomly allocated, stratified according to severity of symptoms and sex, to intensive cognitive behaviour therapy and routine care, supportive counselling and routine care (...) receiving routine care alone also experienced more exacerbations and days spent in hospital.Cognitive behaviour therapy is a potentially useful adjunct treatment in the management of patients with chronic schizophrenia.

Full Text available with Trip Pro

1998 BMJ

610. Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study

Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study Sacristan J A, Gomez J C, Martin J, Garcia-Bernardo E, Peralta V, Alvarez E, Gurpegui M Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of the antipsychotic drug olanzapine as a treatmentof refractory schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population 25 patients with treatment refractory

1998 NHS Economic Evaluation Database.

611. The use of olanzapine as a first and second choice treatment in schizophrenia

The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia Cummins C, Stevens A, Kisely S Authors' objectives To assess whether olanzapine should be used as a first or second choice neuroloeptic, instead of a standard neuroleptic at optimal dose, in the treatment of acute episodes of schizophrenia. The evidence concerning (...) the long-term use of olanzapine was considered, specifically in treatment of acute episodes of schizophrenia as a second choice neuroleptic in cases with poor compliance, non-response or adverse reaction to initial treatment. Searching The electronic databases searched included MEDLINE, Science Citation Index, EMBASE, DARE, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register, ISI Conference Proceedings and Transcripts, NHS EED; the search dates were not reported. Handsearches

1998 DARE.

612. The use of olanzapine as a first and second choice treatment in schizophrenia

The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia Cummins C, Stevens A, Kisely S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cummins C, Stevens (...) A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. Southampton: Wessex Institute for Health Research and Development (WIHRD) (ColLaborative effort with West Midlands Health Technology Assessment ColLaboration, Department of Public Health and Epidemiology) 1998 Authors' objectives The authors assess whether olanzapine should be made available as a first and second line agent for the treatment of all people with schizophrenia. Authors' conclusions The authors

1998 Health Technology Assessment (HTA) Database.

613. The use of olanzapine as a first and second choice treatment in schizophrenia

The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia The use of olanzapine as a first and second choice treatment in schizophrenia Cummins C, Stevens A, Kisely S Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cummins C, Stevens A, Kisely S. The use (...) of olanzapine as a first and second choice treatment in schizophrenia. Birmingham: West Midlands Health Technology Assessment Collaboration (WMHTAC). DPHE Report No. 10. 1998 Authors' objectives To summarise the effectiveness and cost-effectiveness of olanzapine as a first and second choice treatment in schizophrenia. Authors' conclusions Schizophrenia remains a significant health problem despite neuroleptic drugs. Many patients are refractory and others experience significant side effects. Social

1998 Health Technology Assessment (HTA) Database.

614. Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics

Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics Bech P, Peuskens J C, Marder S R, Chouinard G, Hoyberg O J, Huttunen M O, Blin O, Claus A Authors' objectives To assess (...) the benefits and the risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. Searching Not stated. Publication dates of included studies ranged from 1992 to 1995. Study selection Study designs of evaluations included in the review Double-blind randomised controlled trials (RCTs). Follow-up ranged from 4 to 12 weeks. An intention-to-treat (last observation carried forward) analysis was performed. Specific interventions included in the review Risperidone (fixed dosage of 4mg

1998 DARE.

615. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms

Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms Lewis R Authors' objectives To evaluate the efficacy (...) interventions included in the review The following antipsychotic and neuroleptic drugs were included: typical antipsychotics including loxapine, haloperidol, thioridazine, and thiothixene; and atypical antipsychotics including clozapine, risperidone, and olanzapine. Some studies allowed antiparkinsonian medications where necessary. Participants included in the review Children and adolescents of both sexes with psychotic disorders including schizophrenia were studied. Schizophrenic patients included those

1998 DARE.

616. Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies

Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies Mojtabai R, Nicholson R A, Carpenter B N Authors' objectives To investigate the role of psychosocial treatments in management of patients (...) with schizophrenia. Specifically, the following questions were addressed: 1. Does the addition of a psychosocial treatment to a standard medical regimen enhance treatment outcome? And if so, what is the magnitude of this added effect? 2. How do different moderators (in particular, modality and orientation) affect the results of psychosocial treatment? 3. How durable are the results of psychosocial treatments? Searching PsycLIT (1974-94) and MEDLINE (1966-94) were searched. In addition, recent issues

1998 DARE.

617. A cost-effectiveness clinical decision analysis model for schizophrenia

A cost-effectiveness clinical decision analysis model for schizophrenia A cost-effectiveness clinical decision analysis model for schizophrenia A cost-effectiveness clinical decision analysis model for schizophrenia Palmer C S, Revicki D A, Genduso L A, Hamilton S H, Brown R E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Anti-psychotic treatment strategies for patients with schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Hypothetical cohort of patients who had experienced multiple episodes of schizophrenia. Patients with first-episode schizophrenia and treatment-resistant schizophrenia were not considered. Setting Hospital

1998 NHS Economic Evaluation Database.

618. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia

Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, Henderson W, Charney D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Clozapine use in the treatment of refractory schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with refractory schizophrenia with at least 30-364 days

1998 NHS Economic Evaluation Database.

619. Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. (PubMed)

Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. 9130948 1997 05 20 2018 05 23 0140-6736 349 9060 1997 Apr 26 Lancet (London, England) Lancet Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. 1221 Williams J J McGuffin P P Nöthen M M Owen M (...) J MJ eng G9309834 Medical Research Council United Kingdom Letter Meta-Analysis Multicenter Study England Lancet 2985213R 0140-6736 0 Receptors, Serotonin AIM IM Alleles Case-Control Studies Exons genetics Humans Polymorphism, Genetic genetics Receptors, Serotonin genetics Schizophrenia genetics 1997 4 26 1997 4 26 0 1 1997 4 26 0 0 ppublish 9130948 S0140-6736(05)62413-0

1997 Lancet

620. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. (PubMed)

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Clozapine, a relatively expensive antipsychotic drug, is widely used to treat patients with refractory schizophrenia. It has a low incidence of extrapyramidal side effects but may cause agranulocytosis. There have been no long-term assessments of its effect on symptoms, social functioning, and the use (...) and cost of health care.We conducted a randomized, one-year, double-blind comparative study of clozapine (in 205 patients) and haloperidol (in 218 patients) at 15 Veterans Affairs medical centers. All participants had refractory schizophrenia and had been hospitalized for the disease for 30 to 364 days in the previous year. All patients received case-management and social-rehabilitation services, as clinically indicated.In the clozapine group, 117 patients (57 percent) continued their assigned

1997 NEJM